News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
CorWave appoints Dawn Sadlowski-Buisserez– Ysios Capital
Clichy, France, April 2nd, 2025 – CorWave, a French company developing and manufacturing innovative cardiac assist devices, announces the appointment of Dawn Sadlowski-Buisserez as Vice President of Operations. Dawn Sadlowski Buisserez brings extensive experience in implantable medical devices to support CorWave's production scale-up. Her expertise is a major asset for CorWave’s industrial development and its
– Ysios Capital
Focused on the evaluation of strategic alternatives Adopted a restructuring plan to extend capital resources, incurring a reduction in workforce of 30% to support the evaluation of strategic options and the Phase 1 study for LAVA-1266 Phase 1 enrollment in LAVA-1266 clinical trial underway Johnson and Johnson development milestone of $5.0 million achieved and received
Mineralys Therapeutics Late-Breaking Data from Advance-HTN Pivotal Trial – Ysios Capital
Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile Lorundrostat is a highly selective aldosterone synthase inhibitor that disrupts aldosterone biosynthesis rather than blocking the mineralocorticoid receptor Data from Advance-HTN support the potential of lorundrostat
Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress – Ysios Capital
Clinical Complete Responses Observed with Single Low-Dose of Bel-sar in Patients with Intermediate and High-Risk NMIBC with Robust Cell-Mediated Immunity and Urothelial Field Effect Favorable Safety Profile; Only Grade 1 Drug-Related Adverse Events Reported in Less Than 10% of Patients Data Supports Potential for a Paradigm Shifting Approach in the Front-Line Treatment of patients with NMIBC
SpliceBio Announces First Patient Dosed – Ysios Capital
SB-007 addresses the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations SB-007 is the first dual AAV gene therapy in clinical development for Stargardt disease BARCELONA, SPAIN, 13 March 2025 – SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in
Mineralys Therapeutics Public Offering of Common Stock – Ysios Capital
RADNOR, Pa., March 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that it has commenced an underwritten public offering of $250.0 million of shares of
MedLumics FIM Results for AblaView® – Ysios Capital
MADRID--(BUSINESS WIRE)- March, 5 2025 -“We would like to thank the investigation site team and particularly the investigators and proctors in this groundbreaking first-in human trial and for enabling the publication of these important validating results.” Peter Hinchliffe, CEO MedLumics “Join us as we raise our Series B funding of €15m to reach our regulatory clinical trial
– Ysios Capital
Dr. Aleix Prat, an internationally recognized leader in drug and biomarker development appointed Chair of the Advisory Board Dr. Jutta Amersdorffer appointed as Chief Medical Officer and Stéphane Durant des Aulnois appointed as Chief Financial Officer Accelerating development of first-in-class ADCs in multiple large solid tumor types designed against novel targets with a focus on
Mineralys Therapeutics Completes Enrollment – Ysios Capital
Continues to anticipate announcing topline data from Explore-CKD trial in Q2 2025 RADNOR, Pa., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that it
SparingVision advances PRODYGY trial into Phase II – Ysios Capital
DSMB confirms favorable safety profile of SPVN06 across all three doses in patients with severe advanced rod-cone dystrophy (RCD)(n=9) Trial to progress to phase II to evaluate the two highest doses of SPVN06 in patients with intermediate advanced RCD Paris, 21 January 2025 – SparingVision (“the Company”), a clinical-stage genomic medicine company transforming the treatment
Anaconda Biomed Appoints Trent Reutiman New CEO – Ysios Capital
Seasoned Medtech Executive to Expand Company Presence Into U.S. BARCELONA, Spain & MARIN, Calif.--(BUSINESS WIRE)-- Anaconda Biomed S.L., a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, has announced that it has named long-time medtech executive Trent Reutiman as its new CEO. Based in California’s San Francisco Bay Area, Reutiman
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension – Ysios Capital
Obstructive sleep apnea Mineralys’ third precision, targeted indication for lorundrostat, further expanding its market potential in aldosterone-driven diseases
Kynexis Announces Positive Topline Results – Ysios Capital
KYN-5356, an innovative, first-in-class small molecule inhibitor of KAT-II, a key enzyme in the kynurenine pathway implicated in schizophrenia, was shown to be safe and well-tolerated in the phase 1 study in healthy volunteers Initial data show clear evidence of target engagement and suggestive evidence of cognitive improvement, adding to body of evidence that supports
SpliceBio Announces U.S. FDA IND Clearance of SB-007 – Ysios Capital
SB-007 is the only IND-cleared, clinical-stage therapeutic addressing the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations Phase 1/2 ASTRA study set to begin in the first half of 2025, supported by POLARIS, a pioneering company-sponsored natural history study in Stargardt disease First ever IND clearance for
– Ysios Capital
Statistically significant difference in arrested disease in leriglitazone treated patients when compared to the natural history of the disease Submission of European marketing authorization application (MAA) for leriglitazone expected mid-2025 Barcelona, Spain and Düsseldorf, Germany – 11 December 2024 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central
QIAGEN Strengthens QIAstat-Dx With New Barcelona Site– Ysios Capital
New Barcelona site to help drive global expansion of QIAstat-Dx as QIAGEN expands local presence with multi-year investment Site in Esplugues de Llobregat to serve as an innovation hub for QIAstat-Dx, supporting the development of infectious disease tests and precision medicine applications BARCELONA, Spain & VENLO, the Netherlands--(BUSINESS WIRE)-- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA)
Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First- in-class ADC Pipeline – Ysios Capital
Financing led by TCGX, including new investment from TPG, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, with participation from all existing investors Proceeds will be used to support the advancement of multiple first-in-class ADC programs into the clinic and through clinical proof of concept Copenhagen, Denmark – November
Xeltis announces FDA Breakthrough Device Designation for aXess – Ysios Capital
Designation recognizes aXess has the potential of providing a more effective vascular access option for dialysis patients, bringing significant advantages over current therapies First patient treated in US pivotal trial, marking significant clinical milestone EINDHOVEN, The Netherlands, 14 November 2024 - Xeltis, a leading developer of transformative implants that enable the natural creation of living
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update – Ysios Capital
Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025 Ongoing enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 – Conference call today at